Actinium Pharmaceuticals has launched a first-of-its-kind clinical trial evaluating Actimab-A in combination with venetoclax and ASTX-727 for newly diagnosed acute myeloid leukemia patients unsuitable for intensive chemotherapy.
A 13-year-old with relapsed acute myeloid leukemia (AML) achieved full remission through a clinical trial at MD Anderson using a novel menin inhibitor combination.